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Previous studies of the gastroprotective activity of plants have highlighted the importance of the polyphenolic compound epicat-
echin (EC) in the treatment of gastric ulcers. This paper aimed to evaluate and characterize the gastroprotective mechanism of
action of EC using male rats. The gastroprotective action of EC was analyzed in gastric ulcers induced by ethanol or indomethacin.
The involvement of sulfhydryl (SH) groups, K
+
ATP channels, α2 adrenoceptors, gastric antisecretory activity, and the amount of
mucusinthedevelopment ofgastriculcers wereinvestigated. Thelowest eﬀectivedoseofECprovidinggastroprotectiveeﬀectswas
50mg/kgintheethanol-inducedgastriculcersand25mg/kgintheindomethacin-inducedgastriculcers.Thegastroprotectionseen
upon treatment with EC was signiﬁcantly decreased in rats pretreated with a SH compound reagent or an α2-receptor antagonist,
but not with a K
+
ATP channel blocker. Furthermore, oral treatment with EC increased mucus production and decreased H+ secre-
tion. Immunohistochemistry demonstrated the involvement of superoxide dismutase (SOD), nitric oxide (NO), and heat shock
protein-70 (HSP-70) in the gastroprotection. These results demonstrate that EC provides gastroprotection through reinforcement
of the mucus barrier and neutralization of gastric juice and this protection occurs through the involvement of SH compounds,
α2-adrenoceptors, NO, SOD, and HSP-70.
1.Introduction
Gastric ulcers aﬀect thousands of people worldwide and are
considered a global health problem. The pathophysiology of
gastric ulcers is related to the disequilibrium between harm-
ful and protective factors in the gastric mucosa. Agents that
may initiate the development of an ulcer include the follow-
ing: acid and pepsin secretion, Helicobacter pylori infection,
poordiet,alcoholingestion,andtheuseofnonsteroidalanti-
inﬂammatorydrugs(NSAIDs).Protectivefactorsincludethe
following: an intact mucosal barrier, adequate mucus secre-
tion and blood ﬂow, cellular regeneration, prostaglandin
secretion, and epidermal growth factor release [1, 2].
Thecurrenttreatmentoptionsforpatientssuﬀeringfrom
gastric ulcers include antacids, sucralfate, prostaglandins,
muscarinic antagonists, histamine-2 receptor antagonists,
and proton pump inhibitors. However, the long-term use of
these drugs may cause side eﬀects such as hypersensitivity,
arrhythmia, impotence, gynecomastia, and hematopoietic
disturbances [3]. Additionally, their use does not necessarily
prevent the recurrence of the disease.
H. pylori infection has been implicated in the pathogen-
esis of active and chronic gastritis, peptic ulcer, and gastric
carcinoma [4]. The triple therapy, based on a proton pump
inhibitor combined with clarithromycin and amoxicillin
and/or metronidazole, has been the established ﬁrst-line
therapy over the past years to eradicate H. pylori infections
[5–7]. Standard triple therapy started from eradication rates
of more than 90%; however, until now it has experienced a
steady decline, decreasing to 70–80% [8]. There are several
reasons for the loss of eradication eﬃcacy, but the most
important is the increasing rate of H. pylori resistance to
antibiotics [9].
This circumstance evidences the need for new research to
discover substances that would eﬀectively heal gastric ulcers
with fewer side eﬀects. The medicinal plants are attractive
sources of new biomolecules, particularly in the developing
world where infectious diseases are endemic and modern2 Evidence-Based Complementary and Alternative Medicine
health facilities are not always accessible [10]. Although
modern medicine may be available in many developing
countries, natural medicines have maintained popularity for
historicalandculturalreasons.Concurrently,manypeoplein
developedcountrieshavebeguntoturntocomplementaryor
alternative therapies, including medicinal herbs [11, 12].
Polyphenols, which include ﬂavonoids and tannins, are a
group of phytochemicals that have been intensely researched
and are known to exert beneﬁcial eﬀects on health [13],
including experimental gastroprotective action.
Epicatechin (EC, Figure 1), an isomer of catechin, is a
polyphenolic compound present in several plant species.
Previous studies have shown the gastroprotective activity of
Mouriri pusa [14] in which the EC was the main compound
of the extract. Based upon this research, we sought to char-
acterize the mechanism of action of EC in gastroprotection.
2.MaterialandMethods
2.1. Epicatechin: Determination of Doses and Vehicle Used.
(−)-Epicatechin (catalog number 855235) was purchased
from Sigma Chemical Co. (St. Louis, MO, USA). In ethanol
and indomethacin-induced gastric ulcers, the following
doses were tested: 25, 50, and 75mg/kg. The lowest eﬀective
dose was used for all subsequent experiments.
Saline +10% absolute ethanol was used as a vehicle, as
EC is insoluble in 0.9% saline. To avoid diﬀerences between
groups, all drug compounds were solubilized in this vehicle,
including the positive controls.
2.2. Animals. Male Wistar rats (200–250g) from the Central
Animal House of UNESP were fed a certiﬁed diet with free
access to tap water under standard light-dark cycles (12h
dark-12hlight),humidity(60 ±1%),andtemperature(21 ±
2◦C). All rats were fasted prior to each experiment as treat-
ments were orally administered. Additionally, the rats were
housed in cages with raised ﬂoors of wide mesh to prevent
coprophagy. All experimental protocols followed the recom-
mendations of the Canadian Council on Animal Care and
were approved by the UNESP Institutional Animal Care and
Use Committee.
2.3. Experimental Assays
2.3.1. Ethanol-Induced Gastric Ulcers. Male Wistar rats that
hadbeenfastedfor24hweredistributedintosixgroups(n =
7). Animals were then orally dosed with vehicle (10mL/kg),
carbenoxolone(100mg/kg),orEC(25,50,or75mg/kg).The
sixth group (sham) did not receive either drug or vehicle.
After 1 hour, the animals received an oral dose of 1mL of
absolute ethanol. One hour after ethanol treatment, the rats
were sacriﬁced and their stomachs were removed. The stom-
achs were then opened along the greater curvature and
washed. The ﬂattened stomach samples were scanned and
the ulcer area (mm2) was measured using AVSoft BioView
software. A small fragment of each stomach was collected for
glutathione measurement. Stomach samples were collected
for histological slide preparation and stained with hema-
toxylin and eosin (HE) to analyze the morphological and
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Figure 1: Chemical structure of epicatechin.
histological characteristics, or the slides were used for im-
munohistochemical analyses. A microscopic score [15]w a s
determined for the following parameters: epithelial desqua-
mation, hemorrhage, glandular damage, and eosinophilic
inﬁltration, using a scale ranging from 0 to 3 (0: none, 1:
mild, 2: moderate, and 3: severe) for each criterion. The
highest possible score was 12.
Immunohistochemical Analysis. Six slides were used for each
antibody. Each slide was deparaﬃnized, rehydrated, and
immunostained by the ABC method. Nonspeciﬁc reactions
were blocked with H2O2 and goat serum prior to incubation
with a speciﬁc antibody. After rinsing in phosphate-buﬀered
saline (PBS, 0.01Mol/L, pH 7.4), the sections were incubated
in secondary antibody (ABC kit, Easypath Erviegas). The
sections were then washed in PBS buﬀer, the ABC complex
was applied, and the reaction was carried out in a DAB
solution (3,3 -diaminobenzidine-tetrahydrochloride) con-
taining 0.01% H2O2 in PBS buﬀer. After immunostaining,
the sections were lightly counterstained with hematoxylin
and the immunoreactive cells were observed under a Leica
microscope using Leica QWin Software (Leica, UK). In the
control reaction, the slides were processed without the pri-
mary antibody or in the absence of all antibodies. The slides
werestainedwithantibodiesforheat-shockprotein70(HSP-
70), superoxide dismutase (SOD), and nitric oxide (NO)
(Santa Cruz Biotechnology). The marked area (μm2)i ne a c h
slide was measured using AVSoft BioView software.
Determination of Total Glutathione Levels. The total glu-
tathione content in the stomach was quantiﬁed using the
recycling assay [16]. Stomach samples containing ethanol-
inducedgastriculcerswerethawedandminced,diluted 1:20
(w/v) in ice-cold 5% (w/v) trichloroacetic acid, and homog-
enized. The homogenates were centrifuged at 7000g for 15
m i n u t e sa t4 ◦C. The resulting supernatant was used to quan-
tify total glutathione content by reaction with DTNB (5,5 -
ditiobis-2-nitrobenzoic acid). Total glutathione was quanti-
ﬁedbymeasuringtheabsorbanceat412nm.Theresultswere
expressed as nmol total glutathione/g tissue.
2.3.2. Involvement of Sulfhydryl (SH) Compounds in Gastro-
protection. Rats were distributed into four groups (n = 7).
Two groups of rats were intraperitoneally treated with NEMEvidence-Based Complementary and Alternative Medicine 3
(7mg/kg), an SH compound blocker. The other two groups
were treated with vehicle (10mL/kg). One hour later, either
vehicle or EC (50mg/kg) was orally administered to two
groups each. The ulcers were induced following the ethanol-
induced gastric ulcer model and the ulcer area (mm2)w a s
determined with the aid of AVSoft BioView software.
2.3.3. Involvement of K+
ATP Channels or Presynaptic α2-Recep-
torsinGastroprotection. Ratsweredistributedintosixgroups
(n = 7). Two groups of rats were subjected to intraperitoneal
treatment with the following drugs: the K+
ATP channel
blocker glibenclamide (3mg/kg), the α2-receptor antagonist
yohimbine (3mg/kg), or vehicle (10mL/kg). One hour later,
either vehicle or EC (50mg/kg) was orally administered to
two groups each. The ulcers were induced following the
ethanol-induced gastric ulcer model and the ulcer area
(mm2) was determined with the aid of AVSoft BioView
software.
2.3.4. NSAID- (Indomethacin-) Induced Gastric Ulcers. The
rats were distributed into ﬁve groups (n = 7). Vehicle
(10mL/kg), cimetidine (100mg/kg), or EC (25, 50, or
75mg/kg) was orally administered 30 minutes prior to the
induction of gastric lesions by oral administration of the
ulcerogenic agent indomethacin (100mg/kg). The animals
were sacriﬁced 5h after treatment with indomethacin [17].
The stomachs were removed, opened along the greater cur-
vature, and then scanned. The ulcer area (mm2)w a sd e t e r -
mined using AVSoft BioView software.
2.3.5. Evaluation of Gastric Juice Parameters. Male rats were
randomlydividedinto6groups(n = 7).Thirtyminutesafter
oral treatment or immediately after the intraduodenal ad-
ministration of a single dose of vehicle (10mL/kg), cimeti-
dine (100mg/kg), or EC (50mg/kg), the rats were subjected
to pyloric ligation [18]. Four hours later, the animals were
sacriﬁced, the abdomen opened, and another ligature was
placed around the esophagus, close to the diaphragm. The
stomach was removed and its contents were drained into a
graduated centrifuge tube, which was centrifuged at 2000g
for15minutes.Thetotalacidcontentofthegastricsecretions
was determined by titration to pH 7.0 with 0.01N NaOH
using a digital burette (E.M., Hirschmann Technicolor,
Germany). The total concentration of acid was expressed as
mEq/mL/4h.
2.3.6. Determination of Mucus Adherence to the Gastric Wall.
After 24h of fasting, anesthetized rats (n = 7) were subjected
tolongitudinalincisionsslightlybelowthexiphoidapophysis
to place a pyloric ligature. Oral administration of vehicle,
carbenoxolone (200mg/kg), or EC (50mg/kg) was per-
formed 1h before the ligature. After 4h, the animals were
sacriﬁced and the glandular portion of the stomach was
weighedandimmersedinAlcianBluesolutionforthemucus
quantiﬁcation procedure. The absorbance was measured in a
spectrophotometeratawavelengthof598nm,andtheresults
were expressed as μgA l c i a nB l u e / gt i s s u e[ 19].
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Figure 2: Gastric ulcer area (mm2) of rat stomachs (n = 7) with
ethanol-induced gastric ulcers after treatment with vehicle, car-
benoxolone (100mg/kg), or epicatechin (25, 50 or 75mg/kg). The
results are reported as the mean ± SEM, analyzed by ANOVA
followed by Dunnett’s test, ∗P<0.05 and ∗∗P<0.01. ns: not signi-
ﬁcant.
2.4. Statistical Analysis. Parametric data were analyzed using
a one-way analysis of variance (ANOVA) followed by
Dunnett’s test or Tukey’s test and compared to the vehicle
group. The results were presented as the mean ± standard
error of the mean (SEM). Nonparametric data (histology
scoring) were analyzed by the Kruskal-Wallis (nonparamet-
ric ANOVA) test followed by a Dunn multiple comparison
test. The results were presented as the median (range). All
analyses were performed using GraphPad InStat software. A
value of P<0.05 was considered signiﬁcant.
3. Results
3.1. Ethanol-Induced Gastric Ulcers
3.1.1.GastricUlcerArea. Thevehiclegrouppresentedseveral
hemorrhagic bands, with an average ulcer area of 520.41 ±
81.46mm2. The three doses of EC (25, 50, and 75mg/kg)
tested exhibited gastroprotective eﬀects (P<0.05 for the
lowest dose and P<0.01 for 50 and 75mg/kg); however, the
50mg/kg dose exhibited the greatest gastroprotective eﬀect
(94.83% gastroprotection). According to Tukey’s test, there
was no signiﬁcant diﬀerence between the ulcer areas of the
groups treated with 50mg/kg or 75mg/kg; therefore, the
dose of 50mg/kg was used for all subsequent experiments.
T h eu l c e ra r e a s( m m 2) are represented in Figure 2.
3.1.2. Microscopic Score. There was no microscopic evidence
of eosinophilic inﬁltration and hemorrhage, but there was
mild desquamation and glandular damage in the group
treated with 50mg/kg EC. The HE staining of the ulcers is
displayed in Figure 3 and the microscopic score is shown in
Table 1.
3.1.3. Immunohistochemistry. For HSP-70, SOD, and NO,
the immunoreactive areas in the 50mg/kg EC-treated group
were statistically larger (P<0.01) than those in the control4 Evidence-Based Complementary and Alternative Medicine
Table 1: Histological scores (0–12) and immunoreactive areas (μm2) for HSP-70, SOD, and NO in rat stomachs (n = 7) with ethanol-
induced gastric ulcers after treatment with vehicle, carbenoxolone (100mg/kg), or epicatechin (50mg/kg). The scores are represented by
median (range), analyzed by ANOVA followed by Dunn, and compared to vehicle, ∗∗∗P<0.001. HSP-70, SOD, and NO are represented by
the mean ± SEM, analyzed by ANOVA followed by Dunnett’s test, and compared to vehicle, ∗∗P<0.01.
Analysis Vehicle Carbenoxolone Epicatechin
Score 12 (11-12) 4 (2–7)∗∗∗ 3 (2-3)∗∗∗
HSP-70 3718.93 ±479.00 1362.30 ± 244.50∗∗ 7861.07 ± 325.92∗∗
SOD 15631.75 ±956.50 12933.21 ±581.75 26887.53 ± 971.40∗∗
NO 10741.16 ±302.40 11892.80 ±324.72 13686.50 ± 581.96∗∗
Table 2: Eﬀects of epicatechin (50mg/kg) on ethanol-induced gastric ulcer area (mm2)i nr a t s( n = 7) pretreated with the SH reagent NEM
(7mg/kg). The results are expressed as the mean ± SEM and analyzed by an unpaired t-test. P<0.01 compared to the control group, which
was orally treated with vehicle.
Pretreatment (i.p) Treatment (p.o) Gastric ulcer area (mm2) Percentage of gastroprotection
Vehicle Vehicle 251.68 ±46.59 —
Epicatechin 30.11 ±10.61
∗∗ 88.04
NEM (7mg/kg) Vehicle 1157.40 ±266.09 —
Epicatechin 558.70 ±86.11 51.73
#
(a)
∗
(b)
∗
(c)
Figure 3: Photomicrography of rat stomachs with ethanol-induced gastric ulcers after treatment with (a) vehicle, (b) carbenoxolone
(100mg/kg), or (c) epicatechin (50mg/kg). HE staining. ∗Indicates epithelial desquamation, #indicates glandular damage, and the arrow
indicates a hemorrhage arrows indicate hemorrhage.
group. These data indicate their involvement in the gastro-
protective eﬀect of treatment with EC (Table 1).
3.1.4. Determination of Total Glutathione Levels. The treat-
ment with EC (50mg/kg) maintained the total glutathione
level near that of the vehicle and carbenoxolone groups
after the total glutathione-depleting ethanol administration
(Figure 4). However, the total glutathione level in EC-treated
animals was lower than that in the sham-treated group.
3.2. Involvement of NP-SH Compounds, K+
ATP Channels,
or Presynaptic α2-Receptors in Gastroprotection. In rats pre-
treated with NEM (an SH compound reagent), the gastro-
protective eﬀect of EC (50mg/kg) was reversed (Table 2),
indicating the involvement of SH compounds in gastro-
protection. Rats pretreated with yohimbine (an α2-receptor
antagonist)alsoexhibitedareversalingastroprotectionupon
treatment with EC (Table 3), indicating the involvement of
α2-receptors in the protective mechanism of action of EC
(50mg/kg). However, in rats pretreated with glibenclamide
(a K+
ATP channel blocker), the gastroprotective eﬀect of EC
(50mg/kg)wasmaintained(84.14%),indicatingthatthereis
no involvement of the K+
ATP channels in the gastroprotective
eﬀects of EC (Table 3).
3.3. Indomethacin-Induced Gastric Ulcers. The vehicle-treat-
ed group had a large quantity of small petechiae in the stom-
achandameanulcerareaof23.97±4.29mm2.Inthismodel,
the most eﬀective dose of EC was 25mg/kg, which had a
67.83% gastroprotective eﬀect (ulcer area 7.71 ± 1.74mm2,
P<0.01). A dose of 50mg/kg oﬀered 57.90% gastroprotec-
tion (ulcer area 10.09 ± 2.93, P<0.05) and the highest dose
(75mg/kg) was not gastroprotective (43.87%) (Figure 5).
3.4. Evaluation of the Gastric Juice Parameters. A comparison
of the gastric juice parameters of the rats that were treatedEvidence-Based Complementary and Alternative Medicine 5
Table 3: Eﬀects of epicatechin (50mg/kg) on ethanol-induced gastric ulcer area (mm2)i nr a t s( n = 7) pretreated with glibenclamide (K
+
ATP
channels blocker, 3mg/kg) or yohimbine (α2-receptor antagonist, 3mg/kg). The results are expressed as the mean ± SEM and analyzed by
an unpaired t-test. ∗P<0.05 and ∗∗P<0.01 compared to the control group, which was orally treated with vehicle.
Pretreatment (i.p) Treatment (p.o) Gastric ulcer area (mm2) Percentage of gastroprotection
Vehicle Vehicle 599.11 ± 98.78 —
Epicatechin 243.33 ±61.05
∗ 59.39
Glibenclamide Vehicle 134.13 ±16.03 —
Epicatechin 21.27 ±6.00
∗∗ 84.14
Yohimbine Vehicle 602.64 ±102.27 —
Epicatechin 1028.81 ±171.94 0
Table 4: Eﬀects of cimetidine (100mg/kg) or epicatechin (50mg/kg) on gastric juice parameters in rats (n = 7) with pyloric ligation. The
results are expressed as the mean ± SEM and analyzed by ANOVA followed by Dunnett’s test. ∗P<0.05 and ∗∗P<0.01 compared to the
vehicle group.
Route Treatment Gastric juice volume (mL) [H+] mequiv/mL/4h
Oral
Vehicle 1.22 ±0.80 8.03 ±1.28
Cimetidine 1.17 ±0.36 2.49 ± 0.47∗∗
Epicatechin 1.80 ±0.55 4.56 ± 0.56∗
Intraduodenal
Vehicle 3.45 ±0.37 7.82 ±0.45
Cimetidine 2.08 ± 0.16∗∗ 4.20 ± 0.63∗∗
Epicatechin 1.82 ± 0.15∗∗ 7.64 ±1.29
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Figure 4: Glutathione levels (nmol total glutathione/g tissue) of rat
stomachs (n = 7) with ethanol-induced gastric ulcers after treat-
ment with vehicle, carbenoxolone (100mg/kg), or epicatechin
(50mg/kg). The results are reported as the mean ± SEM, analyzed
by ANOVA followed by Dunnett’s test, compared to sham group,
P<0.01.
with EC (50mg/kg) administered by oral or intraduodenal
routes demonstrated that the oral treatment was able to
diminish the H+ concentration in the gastric juice without
modifying its volume. In comparison, the intraduodenal
administration was not able to decrease the H+ concentra-
tion, but it did diminish the volume of the gastric juice
(Table 4).
3.5. Determination of Mucus Adherence to the Gastric Wall.
There was a signiﬁcant increase in the amount of gastric
mucus adhering to the stomach wall in the EC-treated
(50mg/kg) group (2763.07±117.7μg/g, P<0.01) versus the
vehicle-treated group (2211.73 ±98.04μg/g) (Figure 6).
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Figure 5: Gastric ulcer area (mm2) in rat stomachs (n = 7) with
indomethacin-induced gastric ulcers after treatment with vehicle,
carbenoxolone (100mg/kg), or epicatechin (25, 50 or 75mg/kg).
The results are reported as the mean ± SEM, analyzed by ANOVA
followed by Dunnett’s test, compared to vehicle group, ∗P<0.05
and ∗∗P<0.01.
4. Discussion
Commonly used therapies for the treatment of gastric ulcers
often fail to completely heal the ulcers and additionally
p r e s e n tw i t hm a n ys i d ee ﬀects. Furthermore, patients are
searching for new and natural methods of healing their dis-
eases. Therefore, there has been an increased interest in the
search for natural products to treat gastric ulcers. The goal of
thisworkwastocharacterizethegastroprotectivemechanism
of action of epicatechin (EC), which is a polyphenolic com-
pound found in several plant species.
Motawi et al. [20] previously demonstrated that an ele-
vation in gastric acid secretion, neutrophil inﬁltration, and
alterations in NO production and oxidative stress are mech-
anisms that contribute to indomethacin-induced ulceration.6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Quantiﬁcation of adherent mucus (μg/g of tissue) in
the gastric mucosa of rats treated with vehicle, carbenoxolone
(200mg/kg), or epicatechin (50mg/kg), analyzed by ANOVA fol-
lowed by Dunnett’s test, P<0.01.
Indomethacin also induces gastric ulcer formation through
the inhibition of PGE2 synthesis, resulting in a decline in
mucus production and subsequent hemorrhagic ulcers [21].
In the two lowest doses tested in this study, EC was able to
alleviatetheeﬀectsofindomethacinandpreventgastriculcer
formation. The eﬀect of EC seen in this study was not dose-
dependent, which is consistent with previously published
studies on polyphenolic compounds [22–25]. This is most
likely due to the antioxidant eﬀect of lower doses, while
oxidants may be produced at higher doses [26].
Orally administered ethanol causes injury to the gastric
mucosa by decreasing local blood ﬂow [27]. It also decreases
the levels of total glutathione and SH, which are important
gastroprotective factors [28], and depletes the gastric mucus
[29] resulting in gastric lesions. In the ethanol-induced
gastric ulcer assay, the EC protective eﬀect at the three doses
tested suggests a gastroprotective mechanism that acts di-
rectly in the gastric mucosal cells. The intermediate dose
(50mg/kg) was chosen for subsequent assays because its
gastroprotective eﬀect was signiﬁcantly higher than the eﬀect
of the lower dose (25mg/kg) and was not diﬀerent from the
highest dose (100mg/kg).
Themechanismsthatcouldberesponsibleforthegastro-
protective eﬀects were investigated as follows. Endogenous
SH compounds are key agents in mucosal protection against
ethanol-induced gastric injury [30]. These SH compounds
provide protective eﬀects through binding free radicals
formed by ethanol treatment and by controlling the produc-
tion of mucus [31]. Our results evidence the importance of
these compounds in the gastroprotective mechanism of EC.
Moreover, SH compounds are also involved in the mainte-
nanceofthemucusdisulﬁdebridgesthat,ifdamaged,render
the mucus more soluble, resulting in a gastric mucosa that is
more susceptible to injuries caused by harmful agents [32].
The involvement of this pathway in gastroprotection may
also explain why the treatment with EC produced a signiﬁ-
cant increase in the amount of mucus in the gastric glands.
This is an eﬃcient mechanism because the mucus barrier
constitutes the ﬁrst line of mucosal defense as it decreases
mechanic shock, blocks bacterial access to the epithelium
[33], and prevents reverse diﬀusion of H+ ions [34].
The pyloric ligation model permits the evaluation of the
antisecretory actions of an experimental substance for local
or systemic activity. This assay induces ulcers by an in-
crease in gastric hydrochloric acid secretion, leading to auto-
digestion of the gastric mucosa and breakdown of the gastric
mucosal barrier. Orally administered EC exhibited antisecre-
tory activity by decreasing the H+ concentration in the gas-
tric juice without modifying its volume, an eﬀect which did
not occur in the intraduodenally treated rats. These results
lead to the conclusion that EC acts via a local rather than a
systemic mechanism. Furthermore, we suggest that the
decrease in H+ concentration in the orally treated rats can
also be explained by the increase in the gastric mucus pro-
duction stimulated by EC, given that the mucus barrier is
able to neutralize secreted H+.
Gastriccellsproduceseveralantioxidants,includingSOD
andendogenousglutathione,whichscavengereactiveoxygen
species (ROS). An excessive generation of ROS enhances
lipid peroxidation and depletes antioxidant enzymes [35].
SOD is one of the most eﬀective intracellular enzymatic anti-
oxidants, and it acts by catalyzing the dismutation of super-
oxide into oxygen and hydrogen peroxide [36]. Total glu-
tathione is an important antioxidant that is essential in
maintaining the integrity of the gastric mucosa. It prevents
injuries caused by noxious agents through protection from
free-radical-induced damage; however, its levels are reduced
during the ulcerative process [37]. The results indicate that
the gastroprotective eﬀect is not related to the total glu-
tathione pathway but to the SOD antioxidant mechanism.
The antioxidant potential of EC was reinforced by previous
studies showing that EC was able to prevent lipid peroxi-
dation in the rat brain (data not shown). These important
ﬁndings are evidence that the gastroprotective mechanism
of EC is related not only to the reinforcement of the mucus
barrier but also to an antioxidant pathway.
The increase in the immunoreactive area for NO and
HSP-70 is also an important result. NO has attracted con-
s i d e r a b l ea t t e n t i o na sag a s t r i cd e f e n s i v ef a c t o r .T h e r ei ss u b -
stantial evidence that NO, a gas signaling molecule secreted
by the gastric epithelial cells, acts by increasing mucosal
blood ﬂow, regulating the secretion of mucus and bicarbon-
ate, and inhibiting the secretion of gastric juice [38]. It is also
knownthatHSP-70isinducedinsidecellsexposedtostressor
agents.HSP-70proteinsrefoldordegradedenaturedproteins
produced by harmful agents [39], providing resistance to
ulceration.
ATP-sensitive potassium channels (K+
ATP)p r o v i d eag a s -
tric defense by inhibiting neutrophil activation and super-
oxide production and by enhancing gastric microcirculation
[40]. Our data, however, demonstrate that K+
ATP channels
are not involved in the mechanism of action of EC because
the blockade of these channels with glibenclamide did not
reverse the gastroprotective eﬀects of EC.
Our investigation of gastric mucosal protective mecha-
nisms was not focused solely on local mucosal processes.
Presynaptic α2-adrenoceptors mediate several responses in
the gastrointestinal tract, including antisecretory action andEvidence-Based Complementary and Alternative Medicine 7
mucosal protective eﬀects [41], which result in gastroprotec-
tion against diﬀerent types of mucosal damage. The gastro-
protection aﬀo r d e db yE Cw a sr e v e r s e db yy o h i m b i n e ,a n
α2-receptor antagonist, suggesting an active role for α2-
adrenoceptors in gastroprotection.
5. Conclusion
Taken together, these ﬁndings suggest that EC mediates gas-
troprotection through a mechanism that includes the rein-
forcement of the mucus barrier and the neutralization of
gastric juices. Furthermore, this occurs with the involvement
of SH compounds, presynaptic α2-adrenoceptors, SOD, NO,
and HSP-70, in addition to antioxidant eﬀects seen upon
treatment with this compound.
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